euro adhoc: Earnings Forecast / curasan AG: Profit forecast following sale of dental division

--------------------------------------------------------------------------------
Disclosure announcement transmitted by euro adhoc. The issuer is responsible
for the content of this announcement.
--------------------------------------------------------------------------------

11.06.2008

Kleinostheim, June 11, 2008 - Curasan AG (ISIN: DE 000 549 453 8),
listed in the Prime Standard, has sold its dental division to Riemser
Arzneimittel AG, Greifswald, effective from July 1, 2008.

The earnings expected therefrom will amount to a minimum of EUR 15
million and will generate significant one-time income at the end of
the 2008 financial year.

In addition to inventories, the acquirer will take over all
intangible assets attributable to the dental division including the
licences for REVOIS® and Cerasorb®. Furthermore, all shares held in
curasan Inc., USA, as well as part of the workforce will be
transferred to the acquirer.

Curasan AG will remain the manufacturer of the principal product,
Cerasorb®. The company will continue to develop new synthetic bone
regeneration materials and other products for regenerative medicine
and supply these to Riemser Arzneimittel AG as well as to
distribution partners for other fields of indication not associated
with the dental market. All patents and patent filings relating to
Cerasorb® will remain with curasan AG.

About curasan AG: Exchange-listed curasan AG (ISIN DE 000 549 453 8)
is a leading innovator within the market of bone and tissue
regeneration. Alongside its synthetic bone regeneration material
Cerasorb®, the company has established a future-oriented product
pipeline. Several new developments will be ready for market rollout
in the coming years and are to be distributed within various market
segments via well-positioned sales partners. www.curasan.de

About RIEMSER Arzneimittel AG: RIEMSER Arzneimittel AG is a
medium-sized pharmaceutical company with its own research facilities.
Headquartered in Greifswald (island of Riems), Western Pomerania, the
stock corporation operates several sites in Germany. RIEMSER produces
and markets modern active ingredients, pharmaceuticals and dental
products for various areas of application in human and veterinary
medicine. Its products are distributed worldwide. www.riemser.de

end of announcement euro adhoc
--------------------------------------------------------------------------------

ots Originaltext: Curasan AG
Im Internet recherchierbar: http://www.presseportal.de

Further inquiry note:

Information hotline

An e-mail information hotline will be put in place for shareholders and
investors on Wednesday, June 11 from 12:00 to 13:00 hrs (CET). During this
period, your questions should be forwarded to hotline@curasan.de

Branche: Biotechnology
ISIN: DE0005494538
WKN: 549453
Index: CDAX, Classic All Share, Prime All Share
Börsen: Börse Frankfurt / regulated dealing/prime standard
Börse Berlin / free trade
Börse Hamburg / free trade
Börse Stuttgart / free trade
Börse Düsseldorf / free trade
Börse Hannover / free trade
Börse München / free trade